Sber and R-Pharm have developed an AI solution to increase the speed of drug development

2024: Creating a solution to shorten the life of biologics

Sberbank, together with R-Pharm, has developed an AI solution that significantly reduces the time required to create new promising biological drugs. Sberbank announced this on May 17, 2024.

One of the most time-consuming phases in the development of original drugs is the development of a molecule structure with the required characteristics, allowing to achieve the best indicators of efficacy and safety of the future drug. As a rule, only this stage (out of more than a dozen other stages of development) takes about three years of work of specialists. Experts from the Artificial Intelligence Laboratory of Sberbank and R-Pharm have developed an AI solution for generating antibodies, which potentially reduced this stage to two months. Another 10 months should take synthesis and confirmation of the properties of the generated structures in the so-called "wet" laboratory "R-Pharm." Thus, the term for developing the structure of molecules in the future will be reduced by 3 times. Solutions that will allow generating new drugs are actively being developed in Sberbank together with R-Pharm and AIRI.

{{quote 'author = said Sergei Zhdanov, Director of the Health Industry Center of Sberbank. | Pharma is becoming a promising application point for artificial intelligence methods. In the field of design of new molecules, many tasks are associated with generative technologies, and this area of ​ ​ research has been actively developing recently. We have no doubt that there will be significant progress in this area in the near future,}}

Шаблон:Quote 'author = noted Alexander Bykov, director of health economics at R-Pharm.